Compare BCPC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCPC | LEGN |
|---|---|---|
| Founded | 1967 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.9B |
| IPO Year | 1995 | 2020 |
| Metric | BCPC | LEGN |
|---|---|---|
| Price | $166.63 | $16.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $176.00 | $63.08 |
| AVG Volume (30 Days) | 137.2K | ★ 1.2M |
| Earning Date | 04-23-2026 | 03-10-2026 |
| Dividend Yield | ★ 0.58% | N/A |
| EPS Growth | ★ 20.87 | N/A |
| EPS | ★ 4.75 | N/A |
| Revenue | ★ $799,023,000.00 | N/A |
| Revenue This Year | $8.47 | $43.65 |
| Revenue Next Year | $4.89 | $32.75 |
| P/E Ratio | $35.04 | ★ N/A |
| Revenue Growth | ★ 13.56 | N/A |
| 52 Week Low | $139.17 | $16.24 |
| 52 Week High | $183.90 | $45.30 |
| Indicator | BCPC | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.30 | 37.37 |
| Support Level | $165.89 | $16.24 |
| Resistance Level | $171.32 | $20.39 |
| Average True Range (ATR) | 4.02 | 0.74 |
| MACD | -0.41 | -0.14 |
| Stochastic Oscillator | 44.14 | 0.56 |
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.